One Za’abeel’s Coveted One&Only Private Homes and ‘The Residences’ Are Now Available for Sale, Announces Ithra Dubai
Ithra Dubai, a leading real estate developer and asset manager, wholly owned by Investment Corporation of Dubai, announced the highly anticipated sale of One Za’abeel’s One&Only Private Homes and The Residences in Dubai’s most iconic address.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005001/en/
One Za’abeel, the multi-award-winning mixed-used development, is destined to become one of the UAE’s most recognizable architectural icons located right in Dubai’s business center. A marvel of engineering with the world’s longest cantilevered building, it is set to be awarded a GUINNESS WORLD RECORD™.
Suspended perpendicularly across the two towers at a height of around 100 meters and weighing 13,000 tonnes, The Link will host several engaging experiences and will include captivating entertainment venues, dining with celebrity chefs, an infinity pool, an observation deck with uninterrupted 360˚views of Dubai, and an immersive glass-floor experience.
One Za’abeel Tower offers 94 One&Only Private Homes for sale, the pinnacle of urban living in the world’s first vertical urban resort managed by the ultra-luxury One&Only brand. Located in some of the world’s most sought-after destinations, One&Only Private Homes offer upscale private residential sanctuaries with One Za’abeel being no exception. Reflecting the architecture, design, and lifestyle elements for which One&Only is celebrated, One&Only Private Homes offer unparalleled access to the luxury hospitality collection’s world-class resorts, in addition to a series of exclusive benefits.
One Za’abeel’s The Residences houses 264 apartments with a strategic location and lavish facilities. The residences for sale include 1, 2, 3, and 4-bedroom simplexes and duplexes and a 5-bedroom penthouse.
Available for lease in this mixed-use masterpiece is deluxe office space covering an area of 26,000 square and three floors of retail space, F&B, and leisure experiences at the Podium, covering an area of 12,000 square meters.
Strategically located in the heart of the city, at the intersection of Dubai’s famous Sheikh Zayed Road and its commercial business district, One Za’abeel is the gateway to Dubai International Financial District, close to Dubai World Trade Centre, Burj Khalifa, and Dubai International Airport.
“With its mesmerizing architecture, central location, and exceptional mix of offerings, One Za’abeel is an exceptional place to live, work, and spend leisure time in one of Dubai’s most desirable addresses, a true reflection of Dubai’s ambitious spirit,” said Issam Galadari, Director and CEO of Ithra Dubai.
In line with the UAE’s net-zero target for 2050, the development aims to achieve the highest standards of sustainability as it implements the Gold LEED certification requirements in its design and functionality.
About Ithra Dubai
Ithra Dubai LLC, wholly owned by Investment Corporation of Dubai (ICD), develops and manages a portfolio of pioneering real estate projects in Dubai and in key international markets. Its projects are designed to embrace diversity, shape happy communities, and bring prosperity to many. Ithra Dubai aims to deliver mixed-used developments on an ambitious scale, which incorporates world-class retail, commercial, residential, and leisure concepts.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005001/en/
Contact information
Yara Bou Hadir
pressenquiries@sabaconsultants.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom